-26%

est. 2Y upside i

HealthcareSeries D+

Enveda is a biotechnology company that is learning from life’s chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms—the vast majority of which have never been explored by science—creating a database of chemical biodiversity: the library of life.

Rank

#1544

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: High

Enveda presents a moderate upside opportunity driven by its innovative AI-powered natural product drug discovery platform and recent significant clinical progress with multiple assets in Phase 1 and Phase 2 trials.

Last updated: March 10, 2026

Bull (40%)+150%

If ENV-294 achieves strong Phase 2b data in 2026, and ENV-308 or ENV-6946 show promising early clinical results, Enveda's platform validation could drive a significant valuation increase to $3B (2.5x current) within two years, potentially leading to a lucrative acquisition by a large pharmaceutical company.

Base (35%)+40%

Enveda continues to advance its clinical pipeline with positive, but not exceptional, results, securing further funding rounds at a modest step-up. The company's valuation grows to approximately $1.68B (1.4x current) as it progresses towards later-stage trials.

Bear (25%)-40%

Clinical setbacks for lead assets (e.g., safety concerns, lack of efficacy) or a tightening biotech funding market could lead to a flat or down round, reducing the valuation to $0.72B (0.6x current). Given the $517M preference stack, common stock holders would face substantial losses.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

43%

Investors hold $517M in liquidation preferences ahead of common stock. In an exit at or below $1.2B, common stock could see significantly reduced or no returns.

Dilution Risk

high

As a clinical-stage biotechnology company with multiple programs, Enveda will likely require substantial additional funding rounds before potential profitability, leading to further dilution for existing shareholders.

Secondary Liquidity

limited

While platforms exist for accredited investors to trade private shares, market activity for Enveda is described as low, and transactions are subject to company approval.

Questions to Ask at the Interview

Strategic questions based on Enveda's data — designed to show you've done your homework.

  • 1

    “With ENV-294 in Phase 2a for Atopic Dermatitis and Asthma, and ENV-308 and ENV-6946 recently entering Phase 1, how is Enveda prioritizing its pipeline to manage the high capital requirements and regulatory hurdles of multiple clinical programs?”

  • 2

    “Enveda's competitive moat is strong due to its proprietary AI and natural product focus. How does the company plan to maintain this differentiation against well-funded competitors like Recursion Pharmaceuticals and Exscientia, especially as they also advance their AI platforms?”

  • 3

    “Given the Series D funding at a $1.2B valuation and the high funding intensity of 43.1%, what is the company's strategy for managing future dilution for common shareholders, and what is the anticipated timeline for a liquidity event (IPO or acquisition) for employees?”

Community

Valuation Sentiment

Our model estimates -26% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.